Cervical Dysplasia - A Pipeline Analysis Report

Overview of the drug development pipeline for cervical dysplasia

Cervical dysplasia is a pre-cancerous stage, which is caused by human papillomavirus (HPV) infection in the cervix and transmitted through sexual contact. This condition is also known as cervical intraepithelial neoplasia (CIN) and can be mild or severe depending on the appearance of abnormal cells. CIN 1, CIN 2, and CIN 3 are the three types of cervical dysplasia. Patients suffering from this condition experience several symptoms such as abnormal bleeding, genital warts, vaginal discharge, and spotting after intercourse. Technavio’s market research analysts have predicted that with the introduction of loop electrosurgical excision procedure (LEEP) as one of the most promising approach to treat cervical dysplasia, the cervical dysplasia market size will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase II development stage. For instance, sponsors such as AnGes developed BLS-ILB-E710c and Genexine developed GX-188E, which are under phase II stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the phase I, phase I/II, phase III stages.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of cervical dysplasia. In addition to providing information on various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Genexine
• AnGes
• Vaccibody

Therapeutic assessment of the drug development pipeline for cervical dysplasia by route of administration

• Intramuscular
• Topical
• Oral

The intramuscular route of administration (ROA) involves the administration of drug substances directly into the muscle. It has been observed that the majority of total therapeutics are being developed for intramuscular administration.

Therapeutic assessment of the drug development pipeline for cervical dysplasia by therapeutic modalities

• Small molecule
• Antibody
• DNA vaccine

According to cervical dysplasia market forecast, the majority of molecules that are currently in the drug development pipeline for cervical dysplasia are being developed as small molecules. Small molecules are chemically manufactured active substances that are able to enter the cells easily because of their low molecular weight.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for cervical dysplasia?
• What are the companies that are currently involved in the development of drug development molecules for cervical dysplasia?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.